addit ge biopharma busi enhanc
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research may
estim may
price data may
rate updat may
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
uniqu busi impress histor result
strategi reli success manag continu
capital-alloc acumen integr effort manag
histor deal improv underli busi perform
conserv use financ suggest compani remain
disciplin strategi risk deal like pall nobel
cepheid brought innov industri leader
higher growth opportun expens return
capit slid recent year mostli like
long-term outlook major busi wed
like see evid manag wont overpay
follow spin-off anticip spin-off
dental segment becom major player
life scienc diagnost market continu
appreci direct manag capit deploy
life scienc
diagnost remain attract area age
popul demograph growth person medicin
demand biolog manufactur process instal
equip help maintain sticki custom base recur
like manag decis spin dental busi
acquir biopharma busi imagin
spin-off stem dental segment weak
perform although dental industri exposur mostli
cash-pay servic combin fragment custom base
remain attract rise corpor practic buy power
increas commodit mani product categori
weaken growth profit prospect
hand biopharma busi character high
growth high margin larg stream consum sticki
custom base cell cultur media single-us
chromatographi system ge
biopharma asset share signific amount strateg overlap
exist life scienc busi
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
spin-off diversifi mostli
healthcare-focus instrument suppli manufactur
four main busi segment life scienc diagnost dental
environment appli solut repres approxim
revenu respect
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
increas fair valu estim per share
incorpor impend acquisit
ge biopharma busi well cash flow realiz
sinc last updat valuat impli price/adjust
earn multipl approxim
forecast averag annual organ growth
danah next five year nearli organ
growth life scienc diagnost segment
offset slower growth dental environment
appli segment expect danah abl
maintain low- mid-single-digit organ growth
product segment life scienc diagnost
model substanti acquisit ge
biopharma busi set close end year
along small tuck-in acquisit minor
contribut sale growth later year explicit
forecast period howev larger unpredict
deal could drive higher growth expens
capit deploy firm comfort free cash
forecast oper margin rise
near next five year
integr pall cepheid biopharma acquisit
along on-going cost-sav effort
consider margin expans life scienc
diagnost segment expect much margin
improv environment appli
solut busi alreadi post oper margin
assumpt result return invest
capit gradual rise back
estim cost capit approxim
danah diversif presenc mani stabl
industri reduc compani overal risk view
manag consist strategi creat
meaning integr overpay risk manag
abil integr pall ge biopharma busi turn
around nobel oper
profit larg bear near-term
perform exampl therefor give
fair valu estim bull case
assum stronger organ growth help part
better macroeconom condit lead higher
spend equip faster-grow biopharma
consum lead annual organ growth
better-than-expect integr result deal -- particularli
pall cepheid ge biopharma busi -- result
oper margin near return capit also
rise midteen scenario
next
condit manag inabl spur higher
growth product develop market effort
result rel lacklust total annual organ
growth next five year worse-than-expect
integr effort addit weak top-lin perform
doesnt allow manag effici scale
oper lead modest margin expans
high teen return capit bare reach
bear-cas scenario result fair valu
estim
maintain narrow moat rate danah
follow spin-off includ
test measur oper fluke tektronix
root industri technolog segment
kollmorgen thomson jacob vehicl danah
remain diversifi predominantli healthcare-focus
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
cepheid busi rel high switch
cost larg instal base equip becom
essenti compon custom workflow
system stabl instal base equip support
consist pull-through consum make
bulk sale divis
intend spin dental segment
includ implant acquir nobel deal
orthodont ormco specialti dental product
gener sold directli specialist demand newer
innov technolog high-qual materi
hesit switch brand due previou train
also major player dental imag equip
although typic market leader
product categori remain larg signific
player industri innov sticki
relationship help preserv compani brand danah
number-four player diagnost exampl
compet heavili roch siemen abbott
high-volum clinic chemistri immunoassay market
also contend hematolog
compet sysmex anatom patholog
compet primarili roch agil molecular
diagnost asset acquir cepheid pit compani
player like roch biomerieux
second-largest dental player dentspli
acquisit nobel make compani one
key innov premium implant market danah
filtrat water busi compet compani
like ge siemen
think danah moat trend stabl dont forese
major disrupt technolog risk competit headwind
compani market modest innov
keep competit advantag stabl
manag like continu use acquisit fill
busi retain life scienc diagnost
dental water qualiti product identif oper
recur consum revenu make
benefit
predominantli switch cost intang asset
also like gain modest benefit economi
scale layer adjac busi roll-up
acquisit gain consolid
improv sell distribut
purchas
effici compet
mani
commodit market howev differenti product
innov meet custom need remain
critic moat sourc view
 strategi continu focu mostli nich
oligopolist market high barrier entri creat
combin complex
instrument high switch cost extens brand
recognit nearli revenu spin-off
life scienc diagnost segment
includ legaci beckman coulter sciex leica pall
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
area compani lack industri presenc
recent cepheid deal attain access
bolster life scienc diagnost oper
expand product breadth build greater
capabl area ga liquid chromatographi
although plan spin dental busi
think segment face greatest risk
competit pressur equip
specialti dental product help partial insul
compani competit think dental industri
overal face increas commodit price
pressur cheaper altern custom exert
buy power supplier
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
post impress record deal
enabl creat competit busi
boost asset perform focu
improv effici market leadership
odanah shift healthcar market creat less
cyclic busi attract market high
entri
plenti opportun consolid
improv perform variou fragment
nich healthcar market especi life scienc
diagnost
 strategi find busi
attract healthcar market led roic declin
year especi pursuit implant
manufactur nobel filtrat purif
outstand leader
market roch siemen larger
potenti innov competitor
osom market
exampl nobel previous suffer low-
price open-sourc competit lucr
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
strategi think compani maintain rel healthi
financ thank strong oper cash flow combin
fairli conserv use credit equiti financ
increas financ pall acquisit follow
cepheid acquisit debt remain
manag produc healthi cash flow
cover debt oblig pay small dividend
compani net debt/adjust ebitda fell time
end danah ebitda interest coverag ratio
histor remain time compani
dividend yield
danah diversif presenc mani stabl
industri reduc compani overal risk view
manag consist strategi creat
meaning integr overpay risk manag
abil integr pall turn around nobel oper
improv cepheid profit larg bear
near-term perform exampl therefor give
aggress strategi creat risk
compani particularli manag begin consist
overpay asset integr effort larg
busi fail make gain materi danah
on-going shift healthcar also expos firm
market requir consist innov howev
manag stabl histori integr busi
sustain growth profit overleverag
balanc sheet help keep risk
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
capit research manag compani
share
fund
share
fund
compani moder level risk
histor perform sharehold align
firm view although recent declin return
invest capit reason concern
favor view manag histor capital-alloc
decis focus asset industri
certain attract characterist combin
manag abil improv oper perform
danah busi system includ
continu improv empow leadership
focus custom need combin enabl
becom major player mani attract
market materi improv mani acquir
busi impair rare compani
support view manag follow
disciplin strategi process think dental
segment manag intend spin
one area under-perform
compani recent histori manag may stuck
busi long given recent competit
headwind applaud decis separ
cofound brother mitchel steven rale retain
influenc compani creat
mitchel rale chairman execut committe
steven rale chairman board cumul
approxim outstand share thoma
joyc join becam ceo
follow mani previou leadership posit
compani recent water qualiti life scienc
diagnost segment joyc also join rale
brother compani board donald ehrlich
lead independ director board sinc
matthew mcgrew -- previous led
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financ firm diagnost dental divis -- replac
retir daniel coma cfo director elect
annual execut compens mostli tie adjust
ep target also includ free cash flow ratio return
invest capit metric wed prefer return
capit play larger role determin compens
 a-heavi firm like think
compani compens structur fairli shareholder-friendli
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
continu review transfer
coverag new analyst expect publish new fair
valu estim later may
place review transfer
coverag new analyst expect publish new fair
valu estim second quarter
mostli favor outlook danah plan
acquir biopharma busi billion
approxim billion includ expect
billion tax benefit mani way acquisit isnt major
surpris sinc busi fit mold danah
strateg direct -- high growth high margin busi
larg stream consum sticki custom
product chromatographi system biopharma
asset share signific amount strateg overlap
danah exist life scienc busi overal dont
expect dramat shift fair valu estim
incorpor acquisit model also
dont expect chang narrow moat rate view
transact increment posit danah
think purchas price impli roughli time
ebitda look fair especi given segment high
exposur biopharma custom group boost
danah exposur attract portion life
scienc market biopharma custom segment
offer higher growth outlook thank demand biolog
drug develop manufactur also sticker
base user around regul input approv
pharmaceut product manag expect
growth asset may conserv
manag like priorit invest higher
growth portion busi single-us
technolog gene therapi product
thank larg part larg consum mix near
sale alreadi high profit manag
see million cost synergi three year
impli impress ebitda margin near
manag also expect initi boost
adjust ep first year like doubl within five
past year purchas
life scienc diagnost market
manag will take long-term view return
invest capit high single-digit return expect
five year
lastli expect deal close fourth
quarter financ deal cash hand new debt
issu near billion equiti like
inherit pension liabil ge manag
expect bbb credit rate follow transact
manag also announc intend ipo
dental busi -- potenti share initi
issu -- rather previou spin-off plan
bear window narrow thesi play ge
sell biopharma feb
agre sell biopharma busi
approxim billion includ billion cash
assumpt certain pension liabil time
forward ebitda specul deal
possibl earli last year wrote deal would
approxim billion current forward enterpris
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
value/ebitda multipl unit join
danah life scienc stand-alon busi
pharmaceut diagnost current form part
ge life scienc stay remaind ge
healthcar busi suppli contrast media
molecular imag consum radiolog custom
carve-out clearli make sens us given synergi
remain ge healthcar core medic imag
busi still evalu full impact
transact mostli time overli surpris
deal dont expect materi chang ge
fair valu estim per share
express interest busi earli
spring report wall street journal
time howev ge reportedli interest
pursu deal ge lose one bright star
typic increas top line high-single-digit
year-over-year clip think ceo larri make
right strateg decis first deal may make
life scienc valuat current high deal offer
team opportun de-lever balanc
sheet second believ ge life scienc littl
strateg valu futur industri infrastructur
final perhap importantli asset price discoveri
valuabl asset rel line
expect contrast bear assert ge
forc fire sale desir asset
dig self-impos debt hole
believ bear argument
particularli concern ge capit liabil thu
far seem less pronounc initi fear furthermor
ge gener adjust industri free cash flow
billion oper futur remain
strain power believ confirm thesi
ge highli desir asset exceed current
expect fulli valu time
ge transport merger close feb
updat explicit forecast expect
concurr file week
though currenc tariff repres small hurdl
plan make adjust model narrow-
moat compani fourth-quart result
larg keep compani line expect
manag outlook adjust ep
initi forecast think like
compani start year conserv tone
especi modest headwind china-rel
tariff combin neg currenc effect econom
growth concern china also dont seem affect
compani far manag note on-going broad-
base double-digit growth countri quarter
recent result expect organ
growth quarter life scienc segment
remain highest growth divis thank larg part
growth beckman life scienc sciex phenomenex
pall segment pall particular continu wit
double-digit growth among biotech custom group
rate manag note greater stabil
 market healthi perform china
still earli stage launch clear align
busi could add nice tailwind dental
segment lead expect spin-off busi
later year lastli growth diagnost
growth environment appli segment mostli
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
chromatographi mass spectrometri market led
water agil creat one wide-moat
segment benefit low disrupt risk high
barrier entri comfort oligopoli razor-and-
blade busi model high custom switch cost
outlook life scienc diagnost market
remain stabl attract pocket growth
estim market exce roughli billion grow
nearli annual depend market
segment popul growth increas drug research
volum workflow improv rise manufactur
qualiti standard emerg field genet research
test key industri growth driver
complet overview life scienc moat analysi
pleas see report life scienc diagnost industri
offer attract growth econom moat wari
valuat discuss growth outlook
econom moat life scienc industri
match forecast
fourth-quart oper margin bit
weaker anticip basi point
form last year dont anticip materi shift
futur profit assumpt addit acquisition-
currency- tariff-rel pressur bottom line
also
invest certain
initi clear align opportun dental
segment regardless long term still see
integr effici improv effort well
life scienc diagnost industri offer attract
growth moat wari valuat
think plenti like life scienc
sever competit advantag lead econom
moat industri tend predict
attract growth outlook especi area
bioprocess analyt instrument genom
addit somewhat insul broader
macroeconom cycl nearli everi compani life
scienc diagnost manufactur coverag also earn
econom moat thank intang often pair
high switch cost valuat alreadi reflect
optim howev multipl across industri
look expens view current think water
agil becton dickinson reflect best
valu trade close territori view mettler
biomerieux significantli overvalu
moat common life scienc tool thank intang
switch cost gener award moat life
scienc diagnost firm record consist
innov larg instal base equip
dedic pull consum
nich ga
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
